TrivarX R&D program advances MEB-001 algorithm for screening of depressive episodes

Small Caps11-07

An extensive research and development (R&D) program by mental health technology company TrivarX (ASX: TRI) has advanced the company’s proprietary artificial intelligence-backed algorithm MEB-001 for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481916672?lang=en_US&edition=fundamental","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/TrivarX-ASX-TRI-depression-screening-tool.jpg","is_english":true,"pubTime":"2024-11-07 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481916672","market":"us","top_or_hot":-1,"title":"TrivarX R&D program advances MEB-001 algorithm for screening of depressive episodes","media":"Small Caps","content":"<div>\n<p>An extensive research and development (R&D) program by mental health technology company TrivarX (ASX: TRI) has advanced the company’s proprietary artificial intelligence-backed algorithm MEB-001 for ...</p>\n\n<a href=\"https://smallcaps.com.au/trivarx-advances-meb-001-algorithm-screening-depressive-episodes/\">Source Link</a>\n\n</div>\n","source":"smallcap_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TrivarX R&D program advances MEB-001 algorithm for screening of depressive episodes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrivarX R&D program advances MEB-001 algorithm for screening of depressive episodes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 08:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://smallcaps.com.au/trivarx-advances-meb-001-algorithm-screening-depressive-episodes/><strong>Small Caps</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>An extensive research and development (R&D) program by mental health technology company TrivarX (ASX: TRI) has advanced the company’s proprietary artificial intelligence-backed algorithm MEB-001 for ...</p>\n\n<a href=\"https://smallcaps.com.au/trivarx-advances-meb-001-algorithm-screening-depressive-episodes/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRI.AU","symbol_name":"TRIVARX FPO","start_time":0,"source_url":"https://smallcaps.com.au/trivarx-advances-meb-001-algorithm-screening-depressive-episodes/","article_id":"2481916672","we_media_id":null,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/TrivarX-ASX-TRI-depression-screening-tool.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481916672","pubTimestamp":1730938007,"sourceInfo":{"source_id":"smallcap_stock","name":"Small Caps"},"weMediaInfo":null,"summary":"An extensive research and development (R&D) program by mental health technology company TrivarX  has advanced the company’s proprietary artificial intelligence-backed algorithm MEB-001 for the screening of current major depressive episode .The algorithm can accurately conduct sleep staging and screen for cMDE in subjects through a single-channel electrocardiogram, using heart rate and heart rate variability metrics as biomarkers.Proof-of-concept testing on 295 subjects in a Phase 2 sleep signal analysis for cMDE produced results including high sensitivity (87%) and specificity (67%) that are considered key parameters required to build an effective screening tool.TrivarX non-executive chair David Trimboli said the newly developed algorithm would present increased potential applications, including multiple hardware platforms and scenarios outside of sleep centres.“MEB-001 has been shown to deliver promising performance metrics, which will be further validated across data generated from o","collect":0,"end_time":0,"defaultTopTitle":"smallcaps.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRI.AU":"TRIVARX FPO","BK7094":"医疗保健技术"},"translate_title":"TrivarX研发计划推进用于筛查抑郁发作的MEB-001算法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRI.AU":1},"content_text":"An extensive research and development (R&D) program by mental health technology company TrivarX (ASX: TRI) has advanced the company’s proprietary artificial intelligence-backed algorithm MEB-001 for the screening of current major depressive episode (cMDE).\nThe algorithm can accurately conduct sleep staging and screen for cMDE in subjects through a single-channel electrocardiogram, using heart rate and heart rate variability metrics as biomarkers.\nProof-of-concept testing on 295 subjects in a Phase 2 sleep signal analysis for cMDE produced results including high sensitivity (87%) and specificity (67%) that are considered key parameters required to build an effective screening tool.\nIncreased applications\nTrivarX non-executive chair David Trimboli said the newly developed algorithm would present increased potential applications, including multiple hardware platforms and scenarios outside of sleep centres.\n“MEB-001 has been shown to deliver promising performance metrics, which will be further validated across data generated from our upcoming pivotal trial,” he said.\n“It will also have the potential to lead to US regulatory clearance, which will strengthen our commercialisation opportunities.”\nMr Trimboli said the requirement for only two biomarkers could potentially increase patient reach for MEB-001 and unlock opportunities in remote patient monitoring, specialist consumer devices and consumer wearables.\nWork is now underway to advance a series of sponsored clinical trials, testing and licensing opportunities using MEB-001.\nPre-submission meeting\nIn September, TrivarX requested a pre-submission meeting with the US Food and Drug Administration (FDA) for the proposed pivotal clinical trial to test the effectiveness of MEB-001 in screening for cMDE.\nThe meeting is expected to finalise the trial protocol and is the final requirement before TrivarX can submit the algorithm for FDA approval via the De Novo pathway.\nSeveral prominent US sleep centres and research organisations are reported to have expressed interest in collaborating on the trial, which Mr Trimboli said could help fast-track completion at high-volume sites.\nThe pre-submission meeting will be held before year-end, with the trial to commence soon after.\nThere is currently no clinically backed screening solution for cMDE, which is commonly underdiagnosed or misdiagnosed.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481916672"}